Cell adhesion molecule ITGB2 promotes CAR-T cell therapy in B-cell malignancies
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.218014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Yang Su und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Northern Jiangsu Institute of Clinical Medicine…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, CD18 Antigens, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Xuzhou Medical University.
Abstract (Originalsprache)
CAR-T cell therapy, as a representative technology in cancer immunotherapy, has demonstrated notable success in the treatment of hematologic malignancies; however, a significant proportion of patients fail to achieve sustained remission. Through the analysis of bone marrow sequencing data prior to CD19 CAR-T cell therapy, we identified cellular adhesion as a pivotal factor influencing clinical outcomes. We developed a model to predict B-ALL treatment efficacy based on the core genes associated with cellular adhesion, which was validated in our clinical cohort. Both in vitro and in vivo experiments revealed that the inhibition or knockout of integrin subunit beta 2 (ITGB2, also known as CD18) in malignant B cells markedly diminished the cytotoxic efficacy of both CD19 and CD20 CAR-T cells against B-lineage tumor cells, with alterations in ITGB2-mediated cytotoxicity linked to the formation of immunological synapses within the tumor microenvironment. Notably, the upregulation of ITGB2 in Nalm6 cells via LPS or Venetoclax significantly augmented the cytotoxic activity of CAR-T cells against Nalm6 cells. Our findings provide a novel predictive model for clinical CD19 CAR-T cell therapy and elucidate a role of the ITGB2 pathway in CAR-T cell-mediated eradication of B-cell malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Northern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Huaian, 223300, Jiangsu Province, China;…
- Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China.
- Second Ward of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China. Electr…
Förderung
- Xuzhou Medical University
Zitieren
APA
Su, Y., Xu, X., Yang, G., Chen, B., Chen, X., Chen, Q., Lv, K., Zhang, Z., Liu, H., Qi, X., Liu, Y., Yang, B., Li, Y., Li, D., Li, S., Wang, C., & Yu, L. (2025). Cell adhesion molecule ITGB2 promotes CAR-T cell therapy in B-cell malignancies. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.218014
Vancouver
Su Y, Xu X, Yang G, Chen B, Chen X, Chen Q, et al. Cell adhesion molecule ITGB2 promotes CAR-T cell therapy in B-cell malignancies. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.218014
BibTeX
@article{Su2025,
author = {Su, Yang and Xu, Xiaodi and Yang, Guang and Chen, Bi and Chen, Xi and Chen, Qiuni and Lv, Kebing and Zhang, Zhe and Liu, Hong and Qi, Xiaoqin and Liu, Yuan and Yang, Baiyan and Li, Yun and Li, Dongnan and Li, Shenglong and Wang, Chunling and Yu, Liang},
title = {Cell adhesion molecule ITGB2 promotes CAR-T cell therapy in B-cell malignancies},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.218014}
}
EUVIMED